Hengrui Medicine: Ruvilumab Tablets Approved for Clinical Trials.

Hengrui Pharmaceuticals announced that the company recently received approval from the National Medical Products Administration for the clinical trial of Rivoluzumab tablets, and will soon initiate the clinical trial. Rivoluzumab tablets are second-generation AR inhibitors, which have a stronger AR inhibition effect compared to first-generation AR inhibitors, and have no excitatory effect. The company's Rivoluzumab tablets were approved for market in 2022, for the treatment of metastatic hormone-sensitive prostate cancer patients with high tumor burden. Currently, there are several second-generation AR inhibitors such as Enzalutamide, Apalutamide, and Darolutamide on the market both domestically and internationally. According to the EvaluatePharma database, global sales of similar products to Rivoluzumab tablets are estimated to reach approximately $11.037 billion in 2024. As of now, the total R&D investment in Rivoluzumab tablets related projects is approximately 693 million RMB.